Disc Medicine Inc. (IRON) - Total Assets
Based on the latest financial reports, Disc Medicine Inc. (IRON) holds total assets worth $750.21 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Disc Medicine Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Disc Medicine Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Disc Medicine Inc.'s total assets have evolved over time, based on quarterly financial data. See Disc Medicine Inc. (IRON) net assets for net asset value and shareholders' equity analysis.
Disc Medicine Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Disc Medicine Inc.'s total assets of $750.21 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Disc Medicine Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Disc Medicine Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Disc Medicine Inc.'s current assets represent 99.6% of total assets in 2025, an increase from 60.9% in 2020.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 54.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Disc Medicine Inc. Competitors by Total Assets
Key competitors of Disc Medicine Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Disc Medicine Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.00 | 37.65 | 14.89 |
| Quick Ratio | 24.00 | 37.65 | 14.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $716.31 Million | $686.86 Million | $159.81 Million |
Disc Medicine Inc. - Advanced Valuation Insights
This section examines the relationship between Disc Medicine Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.49 |
| Latest Market Cap to Assets Ratio | 3.23 |
| Asset Growth Rate (YoY) | 62.4% |
| Total Assets | $806.88 Million |
| Market Capitalization | $2.61 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Disc Medicine Inc.'s assets at a significant premium (3.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Disc Medicine Inc.'s assets grew by 62.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Disc Medicine Inc. (2020–2025)
The table below shows the annual total assets of Disc Medicine Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $806.88 Million | +62.42% |
| 2024-12-31 | $496.77 Million | +34.99% |
| 2023-12-31 | $368.00 Million | +83.81% |
| 2022-12-31 | $200.21 Million | +116.65% |
| 2021-12-31 | $92.41 Million | +1010.84% |
| 2020-12-31 | $8.32 Million | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more